SEC Form 4 · accession 0001209191-15-003887
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bruce I Sachs
Director
Period of report
Jan 9, 2015
Accepted (ET)
Jan 13, 2015 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 9, 2015 | M | 9,861 | $28.40 | A | 31,071 | D | |
| Common StockF2,F3 | Jan 9, 2015 | S | 9,861 | $125.04 | D | 21,210 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $28.40 | Jan 9, 2015 | M | 9,861 | D | — | May 31, 2018 | Common Stock | 9,861 | 139 | D |
Explanation of responses
- F1Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1.
- F2Open market sales reported on this line occurred at a weighted average price of $125.04 (range $125.00 to $125.25).
- F3Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- F4Fully vested.